Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.67 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.67 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.67 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.67 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.67 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.67 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395025 | 1.00 | LRRK2 (0.67) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1394617 | 0.90 | LRRK2 (0.60) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1394615 | 0.90 | LRRK2 (0.60) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1394809 | 0.84 | APP (0.64) | EGFRERBB2PDGFRBNOX4RAF1 | |
| SCHEMBL1394810 | 0.84 | APP (0.64) | EGFRERBB2PDGFRBNOX4RAF1 | |
| SCHEMBL1395409 | 0.82 | LRRK2 (0.76) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1395411 | 0.82 | LRRK2 (0.76) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1395354 | 0.80 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6689420 | 0.80 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3800644 | 0.80 | LRRK2 (1.00) | LRRK2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | LRRK2 408/4885PSEN1 12/4885PSEN2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.